Vallabhaneni, Srilakshmi
Adusumalli, Srinath
Wu, Jingyi
Groeneveld, Peter W.
Gerson, James
O’Quinn, Rupal P.
Article History
Received: 12 February 2024
Accepted: 22 May 2024
First Online: 1 June 2024
Declarations
:
: Our study used deidentified data and was considered exempt from review by the institutional review board at the University of Pennsylvania.
: Not applicable.
: Dr. O’Quinn has received a speaker honorarium for educating PharmDs and medical science liasons at AstraZeneca on the subject of cardio-oncology, although AstraZeneca was not involved in this study in any way, and the subject of this study is not related in any way to that work. Dr. O’Quinn also gave an unbranded lecture to cardiology fellows on the subject of cardio-oncology on behalf of Zoll Medical Devices and Technology Solutions - none of that material was relevant to this manuscript. Dr. Gerson received consulting fees from Genentech, Abbvie. Dr. Adusumalli is employed full-time at CVS Health Corporation. None of the other authors have any relationships with industry that are relevant to this article.